Advertisement
Advertisement

ADCT

ADCT logo

ADC Therapeutics SA

3.63
USD
Sponsored
-0.13
-3.32%
Jan 30, 15:57 UTC -5
Closed
exchange

After-Market

3.65

+0.01
+0.28%

ADCT Earnings Reports

Positive Surprise Ratio

ADCT beat 13 of 22 last estimates.

59%

Next Report

Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$20.24M
/
-$0.28
Implied change from Q3 25 (Revenue/ EPS)
+23.23%
/
-6.67%
Implied change from Q4 24 (Revenue/ EPS)
+19.71%
/
--

ADC Therapeutics SA earnings per share and revenue

On Nov 10, 2025, ADCT reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 18.68% surprise. Revenue reached 16.43 million, compared to an expected 17.42 million, with a -5.69% difference. The market reacted with a +4.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.28 USD, with revenue projected to reach 20.24 million USD, implying an decrease of -6.67% EPS, and increase of 23.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, ADC Therapeutics SA reported EPS of -$0.30, beating estimates by 18.68%, and revenue of $16.43M, -5.69% below expectations.
The stock price moved up 4.21%, changed from $4.04 before the earnings release to $4.21 the day after.
The next earning report is scheduled for Mar 25, 2026.
Based on 8 analysts, ADC Therapeutics SA is expected to report EPS of -$0.28 and revenue of $20.24M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement